据新华社旧金山电，埃隆·马斯克2025年12月31日通过社交平台发布重磅消息，旗下脑机接口公司 Neuralink计划于2026年启动脑机接口设备大规模量产，并同步推出全自动化外科手术流程。这一规划标 志着脑机接口技术从临床验证阶段向产业化落地迈出关键一步，也成为A股人脑工程板块的强力催化， 截至1月5日上午收盘，该板块指数大涨12.56%至6245.59点，超十只概念股收获"20CM"涨停。 据Neuralink官网及马斯克公开发言内容，截至2025年9月份，该公司已完成12例脑机接口设备人体植入 手术，临床试验参与者累计使用设备时长超1.5万小时，患者可通过意念实现光标操控、文字输入甚至 机械臂辅助进食等操作，设备实际运行稳定性达标率超98%。同时，第二代手术机器人实现技术升级， 将单根电极植入时间从17秒压缩至1.5秒，整体手术时长从6小时缩短至20分钟内；成本端也实现大幅下 降，单台设备植入成本从早期百万美元级降至10万美元以内，全自动化手术落地后有望进一步下探至5 万美元区间。 《证券日报》记者注意到，A股相关上市公司早已在脑机接口赛道展开布局，从设备研发到临床应用多 维度切入，试图抢占行业发展先机 ...

Market Overview - The A-share market saw a strong opening on January 5, with the Shanghai Composite Index returning to 4000 points, closing at 4011.45, up 1.07% [1] - The Shenzhen Component Index rose by 1.87%, and the ChiNext Index increased by 2.15% [1] Trading Volume - The total trading volume in the Shanghai and Shenzhen markets reached 1.64 trillion yuan, an increase of 323.8 billion yuan compared to the previous trading day [3] Stock Performance - A total of 4064 stocks rose, with 99 stocks hitting the daily limit, while 1236 stocks declined [3] - The sectors that performed well included insurance, medical devices, semiconductors, and gaming, with brain-computer interface concept stocks experiencing significant gains [3] Sector Highlights Brain-Computer Interface - Brain-computer interface stocks surged, with several companies hitting the daily limit [6] - Notable performers included Xiangyu Medical, Guanhao Biological, Meihua Medical, Aipeng Medical, and Lepu Medical, all recording a 20% increase [6][7] - Elon Musk's Neuralink announced plans for large-scale production of brain-computer interface devices by December 31, 2026, which is expected to revolutionize the field by reducing invasiveness [9] Semiconductor Sector - The semiconductor sector also showed strength, with multiple stocks reaching their daily limit [10] - Key performers included Dongwei Semiconductor and *ST Tianlong, both achieving a 20% increase [11] - TSMC announced it received U.S. government approval to import chip manufacturing equipment to its Nanjing facility in 2026, which is a positive development for the sector [12] Insurance Sector - The insurance sector experienced a rally, with significant gains from major companies [13] - Xinhua Insurance rose by 7.53%, China Pacific Insurance by 6.16%, and China Life Insurance by over 5% [13][14] - The insurance industry reported a total premium income of 57.629 billion yuan for the first 11 months of 2025, a year-on-year increase of 7.6% [14]

Core Viewpoint - The A-share market experienced a significant surge on January 5, 2026, driven by the brain-computer interface (BCI) sector, with the index rising over 12% and multiple stocks hitting their daily limit up [1] Group 1: Market Performance - On the opening day of the A-share market, stocks related to brain-computer interfaces saw a collective rally, with stocks like BeiYikang (920199.BJ) hitting a 30% limit up and others such as Botao Bio (688767.SH) and Sanbo Neuroscience (301293.SZ) reaching 20% limit up [1] - A total of 11 stocks in the BCI sector experienced a 20% limit up, indicating strong investor interest and market momentum [1] Group 2: Technological Developments - The surge in the BCI sector was catalyzed by news of mass production of BCI devices by Elon Musk's company, Neuralink, expected to begin in 2026, which includes advancements in surgical procedures [1] - Neuralink's device will feature electrodes that can penetrate the dura mater without removal, marking a significant technological breakthrough [1] Group 3: Domestic Developments - In China, several companies are emerging that parallel Neuralink's technological approach, with Guotai Junan Securities declaring 2025 as the year for clinical trials of invasive and semi-invasive BCIs [2] - Companies like Borui Kang have completed clinical trials, with expectations for regulatory approval in 2026, while other firms are also making progress in BCI technology [2] Group 4: Market Projections - Open Source Securities predicts that BCI technology will redefine human-robot interaction and is expected to commercialize by 2026, expanding from medical applications to AI and robotics [3] - The global BCI market is projected to grow to approximately $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034, indicating strong future growth potential [3]

Core Viewpoint - The medical sector is experiencing a strong performance, with the largest medical ETF (512170) showing significant gains, driven by positive market sentiment and news regarding Neuralink's plans for large-scale production of brain-computer interface devices starting in 2026 [1][3]. Group 1: Market Performance - On January 5, 2026, the medical ETF (512170) opened high and rose over 4%, potentially marking the largest single-day gain in nearly three months, with real-time transactions exceeding 650 million yuan [1]. - All 50 constituent stocks of the medical ETF saw increases, with notable surges in brain-computer interface stocks, including Sanbo Brain Science, Meihua Medical, and Lepu Medical, which hit the daily limit of 20% [1]. - The CXO sector also performed strongly, with Zhaoyan New Drug reaching the daily limit and WuXi AppTec increasing by nearly 6% [1]. Group 2: Fund and Index Details - The medical ETF (512170) has a total scale exceeding 25.259 billion yuan, making it the largest medical and healthcare ETF in the market, serving as a significant industry benchmark [3]. - The ETF focuses on "medical devices + medical services," with a CXO weight exceeding 26%, and includes leading companies in aesthetic medicine, private hospitals, and medical information technology [3]. - The current price-to-earnings ratio of the underlying index for the medical ETF is 32 times, which is lower than over 70% of the time in the past decade, indicating a favorable cost-performance ratio for investors [1].

Core Viewpoint - Neuralink, founded by Elon Musk, is set to begin large-scale production of its brain-machine interface technology this year, marking a significant advancement in automated surgical procedures and bringing previously speculative technology into mass production [1][4]. Company Developments - Neuralink has announced that it will automate surgical processes, reducing the insertion time for its devices to 1.5 seconds and cutting manufacturing costs by 95% [4]. - As of September 2025, 12 patients with severe paralysis have successfully implanted Neuralink devices, enabling them to perform tasks such as gaming and social media interaction [5]. - The company raised $650 million (approximately 4.55 billion RMB) in a funding round completed in June [5]. Industry Trends - The brain-machine interface sector is experiencing a surge in interest and investment, with companies like阶梯医疗, 博睿康, and 芯智达 entering clinical validation stages [9]. - The Chinese government has included brain science and related research in its "14th Five-Year Plan," aiming for significant technological breakthroughs by 2027 [10]. - The market for brain-machine interfaces in China is projected to grow from 3.2 billion RMB in 2024 to over 5.5 billion RMB by 2027, with global market estimates reaching $40 billion by 2030 [11]. Market Response - Following Neuralink's announcement, stocks related to brain-machine interfaces surged, with notable increases in companies such as 南京熊猫电子股份 (up 43.69%) and 微创脑科学 (up 16.19%) [2][3]. - A-share market also saw significant gains, with multiple companies hitting the upper limit of their trading range [2]. Future Outlook - Neuralink's roadmap includes plans for motion decoding for patients with spinal injuries and visual encoding for those with vision impairments, potentially addressing mental health issues and enhancing cognitive abilities [6]. - The industry is expected to benefit from technological breakthroughs, policy support, and collaborative ecosystems, with a projected CAGR of 17% from 2025 to 2034 [11].

政策端也持续加码支持。国家药监局近期在北京召开脑机接口医疗器械工作推进会，明确表示将加快相 关产品的审评审批流程，推动创新器械更快上市应用。 国金证券指出，在医疗器械创新政策密集落地 背景下，脑机接口作为前沿交叉领域，正迎来从科研验证向临床及消费场景拓展的关键窗口期。 （文章来源：每日经济新闻） 医疗器械ETF（562600）大涨4.36%。截止2025年12月30日，医疗器械ETF脑机接口含量达20.91%。 消息面上，行业迎来多重催化。特斯拉CEO埃隆·马斯克近日在社交媒体透露，其旗下脑机接口公司 Neuralink计划于2026年启动脑机接口设备的"大规模生产"。这一表态被市场视为该技术迈向商业化的重 要信号。 与此同时，由OpenAI首席执行官Sam Altman联合创立的脑机接口初创公司Merge Labs宣布将分拆为独 立实体，专注于开发基于超声波的非侵入式脑信号读取技术。该方案无需植入电极，即可实现对大脑活 动的大范围、高精度解读，有望大幅降低技术门槛与临床风险。 早盘脑机接口概念小幅高开，随后震荡上行，截止10点57分，乐普医疗、美好医疗、翔宇医疗、伟思医 疗、迈普医学封板涨停。 ...

1月5日， 脑机接口板块持续大涨，截至发稿，板块指数涨幅已超11%。 马斯克说，该设备的电极丝将直接穿过硬脑膜，而无需将其切除，此举意义重大。 编辑丨瑜见 倍益康30%涨停，美好医疗、三博脑科、熵基科技、翔宇医疗、诚益通等10股20%涨停，创新医疗、荣 泰健康、南京熊猫、三七互娱等涨停。 | 代码 | 名称 | 式唱 | 息金额 | 息而值 | 现价 | | --- | --- | --- | --- | --- | --- | | 920199 | 倍益康 | +29.98% | 1.96 Z | 30.62 G | 44.96 | | 688767 | 博拓生物 | +20.01% | 6.27 Z | 67.71 Z | 45.34 | | 301293 | 三博脑科 | +20.01% | 7.04Z | 1 45.8亿 | 70.78 | | 301363 | 美好医疗 | +20.00% | 1.98 Z | 164.2 乙 | 28.86 | | 301330 | শ্ব # 技 | +20.00% | 7.25 Z | 93.34 Z | 39.66 | | 300887 | 谱尼测试 | + ...

医疗板块开门红！2026年1月5日早盘，医疗板块全线飘红，全市场规模最大医疗ETF（512170）高开高 走，盘中涨超4%，今日有望创下近3个月来最大单日涨幅！实时成交超6.5亿元。 医疗ETF50只成份股全部上涨，脑机接口概念股集体爆发，三博脑科、美好医疗、乐普医疗20CM涨 停！CXO亦强势，昭衍新药涨停，巨头药明康德涨近6%。 医疗板块开门红！2026年1月5日早盘，医疗板块全线飘红，全市场规模最大医疗ETF（512170）高开高 走，盘中涨超4%，今日有望创下近3个月来最大单日涨幅！实时成交超6.5亿元。 医疗ETF50只成份股全部上涨，脑机接口概念股集体爆发，三博脑科、美好医疗、乐普医疗20CM涨 停！CXO亦强势，昭衍新药涨停，巨头药明康德涨近6%。 消息面上，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备进 行"大规模生产"。 | 分时 多日 1分 5分 · | | | | | | | F9 盘前盘后 露加 九轮 面线 工具 @ 2 > | | | | | | | | | | 医疗ETF O | | | | --- | --- | --- | --- ...

一、行情表现 1月5日，脑机接口板块开盘大涨。三博脑科（20CM）、岩山科技、创新医疗、南京熊猫等集体一字板，塞力医疗、盈趣科技、翔宇医疗（20CM）、荣泰 健康、国际医学、爱朋医疗（20CM）、熵基科技（20CM）、麦澜德（20CM）、诚益通（20CM）、伟思医疗（20CM）、迈普医学（20CM）等集体涨 停。 | 脑科学 +12.41% | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 理由 | | 马斯克旗下脑机接口公司2026年将启动脑机接口设备"大规模生产" | | | | | | 股票名称 | 最新价 = | 涨跌幅 = | 涨停时间 = | 换手率 = | 流通市值 ◆ | 解读 | | 三博脑科 | 70.78 | +20.01% | 09:25:00 | 6.18% | 113.92 乙 | 公司是以神经专科为特色的医疗服务集 | | 301293.SZ | | | | | | 院,其中神经专科医院4家,综合性医院 | | 美好医疗 | | | | | 107.71亿 | 公司正与下游脑机接口客户开展产品合 批量出货的商业 ...

早盘中，人脑工程板块表现活跃。板块内9只个股涨停。三博脑科、翔宇医疗、美好医疗20CM涨停， 熵基科技涨超19%，爱朋医疗、诚益通、麦澜德涨超17%，博拓生物涨超15%，伟思医疗涨超13%，狄 耐克、乐普医疗涨超11%，塞力医疗、岩山科技、荣泰健康、创新医疗、南京熊猫、盈趣科技涨停。 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | | 美好医疗 | 28.86 | 4.81 | 20.00% | | 翔宇医疗 | 72.60 | 12.10 | 20.00% | | 爰朋医疗 | 32.61 | 4.86 | 17.51% | | 乐普医疗 | 17.55 | 1.74 | 11.01% | | 创新医疗 | 23.66 | 2.15 | 10.00% | | 三七互娱 | 25.96 | 2.36 | 10.00% | | 赛诺医疗 | 21.05 | 1.81 | 9.41% | | 汉威科技 | 57.55 | 3.95 | 7.37% | | 冠昊生物 | 14.88 | 1.03 | 7.44% | | 北陆药业 | 8.35 | 0.41 | 5. ...